Sanofi Reaches New 52-Week High (SNY)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Sanofi (NYSE: SNY) hit a new 52-week high Wednesday as it is currently trading at $54.80, above its previous 52-week high of $54.55 with 6,479 shares traded as of 9:30 a.m. ET. Average volume has been 2.9 million shares over the past 30 days.

Sanofi has a market cap of $141.47 billion and is part of the health care sector and drugs industry. Shares are up 14.6% year to date as of the close of trading on Tuesday.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. The company has a P/E ratio of 28.4, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Sanofi Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Sanofi Has Good Potential Upside

European Pharma Companies Slip on MS Pricing Probe